- $1.79bn
- $1.87bn
- $109.79m
Brief: Urogen Says Ugn-102 Met Primary Endpoints In Two Phase 3 Trials
Brief: Urogen Pharma Ltd Announces $120 Million Private Placement Of Ordinary Shares
Brief: Urogen Pharma Announces The Appointment Of James Robinson To Its Board Of Directors
Brief: Urogen Pharma Ltd Board Increased Size Of Board From Eight To Nine Directors
Urogen Pharma up on higher Q1 cancer drug sales
Urogen jumps on takeover buzz
Brief: Urogen Pharma Reports Highest Revenue Quarter And Recent Corporate Developments
In A Small Feasibility Study, Ugn-102 Achieves A Complete Response In 75% (6 Of 8) Patients
UroGen Pharma falls as Jefferies downgrades on commercial underperformance
Brief: Urogen Pharma Ltd Says Results Of The First Post-Commercial Utilization Review Of Jelmyto Provide New Evidence That Reinforces Its Efficacy And Safety In Patients With Low-Grade Upper Tract Urothelial Cancer
Brief: Urogen Completes Enrollment Of Its Phase 3 Clinical Trial For Ugn-102 In Development For Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer
Brief: Urogen Announces New Data From Olympus Trial That Shows Median Durability Of Response Of 28.9 Months For Jelmyto®
Brief: Urogen Pharma Ltd Files For Mixed Shelf Of Up To $250 Mln - SEC Filing
Brief: Urogen Pharma Reports Third Quarter Results
Brief: FDA Authorizes An Extension Of The In-Use Period For Urogen Pharma’S Jelmyto® Admixture To 96 Hours Following Reconstitution
Brief: Urogen Announces The Appointment Of Leana Wen To The Urogen Pharma Board Of Directors
Brief: Urogen Pharma Reports Second Quarter 2022 Financial Results
NASDAQ RESUMED AT 10:04 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:00 AM